Companies Economy Markets

UniQure Seeks FDA Ok For Huntington’s Disease Gene Therapy After Regulatory Reversal

UniQure announced plans to seek FDA approval for its Huntington’s disease gene therapy, following a recent meeting in which the agency signaled that a three-year analysis might support accelerated approval.

Flavor News Editorial Desk 3 min read
UniQure advances Huntington’s disease gene therapy toward FDA review amid shifting agency guidance
UniQure advances Huntington’s disease gene therapy toward FDA review amid shifting agency guidance

Market impact

UniQure’s update highlights a potential accelerated path to market for a Huntington’s disease gene therapy, contingent on confirmatory data and FDA alignment.

Why it matters: The FDA’s evolving stance on trial designs for rare diseases directly affects regulatory timelines, investor sentiment, and funding for Huntington’s therapies.

Key numbers

  • Phase 1/2 study three-year analysis
  • 75% slowdown in disease progression (reported in source)
  • third-quarter submission target
  • 70% share price move (intraday)

Watch next

  • FDA decision on accelerated approval pathway
  • Data corroboration from confirmatory trials
  • Regulatory guidance shifts under FDA leadership
Biopharma Healthcare Equipment & Services UniQure FDA Huntington’s disease patients

Huntington’s disease drugmaker UniQure said it plans to seek approval from the U.S. Food and Drug Administration for its experimental gene therapy, months after a public clash with agency leaders over the evidence backing the application. The company indicated that a three-year analysis from a Phase 1/2 study could support an accelerated approval, signaling a potential path to market contingent on confirmatory data.

UniQure emphasized that, following a recent FDA meeting, the agency suggested the cited three-year analysis would be sufficient to back an accelerated approval. If so, the company aims to file its application with the FDA in the third quarter of this year. Trading reaction reflected the news, with UniQure shares rising sharply on the day of the announcement.

The episode marks a notable reversal from March, when the FDA publicly criticized the company and said its clinical trial data would not support an application. The reversal underscores a broader pattern of changing agency guidance that has affected rare-disease drugmakers, particularly in the period surrounding former FDA leadership.

In discussing the evolving dialogue, UniQure noted that the agency previously questioned whether data from trials using an external control were sufficient to support an application. At that time, a senior FDA official indicated the agency preferred a placebo-controlled trial to demonstrate real benefit. The company has since stated it would be unethical to perform a sham brain surgery, given the treatment is delivered directly into the brain through lengthy surgery; instead, the company used comparative progression data against an external database.

According to UniQure, the analysis showed the gene therapy slowed disease progression by a substantial margin in the Phase 1/2 setting. With the current guidance, the revised plan centers on aligning the study design with standard of care comparisons rather than sham controls, and UniQure vowed to finalize those plans before submitting the application. Huntington’s disease, linked to mutations in the HTT gene, remains a progressive neurodegenerative condition.

The broader context includes notable personnel changes at the FDA, with former leadership leaving during the period of debate. The company said it plans to pursue accelerated approval while continuing to work on confirmatory data obligations post-approval, should the pathway be granted.

UniQure’s decision comes as investors weigh the potential for new therapeutics in Huntington’s disease and the regulatory dynamics affecting rare disease programs. The company did not offer investment guidance, focusing instead on regulatory milestones and data alignment with the FDA.